Lung cancer in Berlin – Therapeutic concepts and their impact on survival in patients with NSCLC stage II/III from 2000 to 2008
T. Blum, S. Eggeling, C. Gogoll, C. Grah, C. Grohé, C. Lauer, G. Leschber, J. Neudecker, W. Pankow, B. Schicke, P. Schneider, N. Schoenfeld, C. Witt, A. Jagota (Berlin, Germany)
Source: Annual Congress 2012 - Treatment of lung cancer
Session: Treatment of lung cancer
Session type: Poster Discussion
Number: 2925
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Blum, S. Eggeling, C. Gogoll, C. Grah, C. Grohé, C. Lauer, G. Leschber, J. Neudecker, W. Pankow, B. Schicke, P. Schneider, N. Schoenfeld, C. Witt, A. Jagota (Berlin, Germany). Lung cancer in Berlin – Therapeutic concepts and their impact on survival in patients with NSCLC stage II/III from 2000 to 2008. Eur Respir J 2012; 40: Suppl. 56, 2925
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Lung cancer in Berlin – NET of the lung; analysis of subgroups and impact on survival (2000 – 2008) Source: Annual Congress 2013 –Epidemiology, screening and diagnosis of lung cancer Year: 2013
Major changes in men with non-small-cell lung cancer (NSCLC) in 10 years: The KBP-2000-CPHG and KBP-2010-CPHG cohorts Source: Annual Congress 2013 –Epidemiology, screening and diagnosis of lung cancer Year: 2013
Prognostic factors affecting survival in cases with lung cancer [A lung cancer mapping project in Turkey (LCMPT)] Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer Year: 2013
Prognostic factors for stage IV lung adenocarcinoma patients receiving retreatment with EGFR-TKI Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours Year: 2015
Impact of second-line treatment on overall survival of advanced lung adenocarcinoma patients Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016
Relapse after radical surgery for non-small cell lung cancer 2005-2009 – A retrospective quality management analysis Source: Annual Congress 2011 - How to improve lung cancer care Year: 2011
A prospective study of survival after surgery for early stage non-small cell lung cancer in patients with COPD Source: International Congress 2015 – Risk assessment and prevention of complications in thoracic surgery Year: 2015
Survival outcomes in advance non-small cell lung cancer – A developing country scenario Source: Annual Congress 2011 - Quality management for lung cancer patients Year: 2011
Comorbitities, responses and survival in pts with NSCLC Source: International Congress 2014 – Epidemiology, pathogenesis and quality management of thoracic tumours Year: 2014
Pemetrexed in maintenance therapy of 164 patients with advanced non-small-cell lung cancer (NSCLC) Source: International Congress 2016 – Lung cancer: therapeutic modalities, re-staging, and follow-up Year: 2016
EGFR mutation diagnostic program for NSCLC patients in Poland between 2011-2014 Source: International Congress 2015 – Promising novel findings in translational pulmonary research Year: 2015
Improved survival associated with neoadjuvant chemoradiation and surgery vs other means of treatment for NSCLC N2 patients (clinical stage IIIa and IIIb) Source: International Congress 2015 – Lung cancer therapy: clinical trials Year: 2015
Lung metastases from colorectal cancer – Surgery, early and late postoperative results Source: Annual Congress 2012 - Instructive clinical aspects of thoracic oncology Year: 2012
Long term results of the randomized phase 2 trial on refinement of early stage NSCLC adjuvant chemotherapy with cisplatin/pemetrexed (CPx) versus cisplatin/vinorelbine (CVb) - TREAT Source: International Congress 2014 – Advances in diagnosis and therapy of thoracic tumours Year: 2014
Comparison of non-small cell lung cancer (NSCLC) management and survival in 1995 and 2005 at a London teaching hospital Source: Annual Congress 2008 - Management, quality aspects and prognosis in thoracic oncology Year: 2008
Development and validation of a prognostic index for survival in patients with non-small-cell lung cancer Source: International Congress 2016 – Prognostic variables in lung cancer II Year: 2016
A new TNM classification is better than ISS at predicting survival in stage III unresectable non-small cell lung cancer (NSCLC). A study by the European lung cancer working party (ELCWP) Source: Eur Respir J 2003; 22: Suppl. 45, 163s Year: 2003
Differences in epidemiological and clinical features in non-small cell lung cancer (NSCLC) in never and ever smokers Source: International Congress 2015 – Diagnosis and therapy of lung cancer Year: 2015
A phase III trial comparing concomitant radiochemotherapy (RT-CT) with cisplatin (P) and docetaxel (D) as induction versus consolidation in patients with locally advanced unresectable non-small cell lung cancer (NSCLC). An ELCWP study Source: International Congress 2015 – Advances in the therapy of lung cancer Year: 2015
Prognostic value of preoperative C-reactive protein in resectable non-small cell lung cancer - 5-years prospective study Source: International Congress 2014 – Diagnosis, imaging and surgery for thoracic tumours Year: 2014